Summary
Seven women were treated with metoprolol 50–100 mg twice daily for hypertension in pregnancy. The disposition of metoprolol and one of its metabolites alfa-OH-metoprolol was studied in venous plasma and amniotic fluid during labour, in mixed cord plasma and in capillary blood of the newborn.
Peak concentrations of metoprolol and alfa-OH-metoprolol were reached 60 to 120 min after dosing in maternal plasma while the amniotic fluid levels of these compounds continued to increase from 60 to 180 min to the end of the study and were substantially higher than in the plasma after 4 to 5 h.
It is postulated that a major fraction of metoprolol and alfa-OH-metoprolol reaches the amniotic fluid via the fetal urine and that the elimination from the amniotic fluid mainly proceeds via diffusion across fetal membranes and transfer across the fetal capillary bed.
No measurable concentrations of metoprolol were found in two of the newborns 2 h after delivery. In the remaining four neonates the 2-h concentrations exceeded the corresponding cord plasma levels. In all neonates the alfa-OH-metoprolol levels in the capillary blood were higher 2 h after birth than in cord blood. In two newborns the metabolite levels continued to increase for 5 h and in one the highest blood concentrations of this metabolite was found 20 h after birth.
Redistribution of metoprolol from tissue stores followed by metabolism might be the cause of these temporary elevations of the blood levels of metoprolol and alfa-OH-metoprolol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sandström B (1982) Adrenergic beta-receptor blockers in hypertension of pregnancy. Clin Exp Hypertens B 1: 127–142
Högstedt S, Lindeberg S, Axelsson O, Lindmark G, Rane A, Sandström B, Lindberg BS (1985) A prospective controled trial of metoprolol-hydralazine treatment in hypertension during pregnancy. Acta Obstet Gynecol Scand 64: 505–510
Lindberg BS, Sandström B (1981) How Swedish obstetricians manage hypertension in pregnancy. Acta Obstet Gynecol Scand 60: 327–331
Benfield P, Clissold SP, Brogden RN (1986) Focus on metoprolol. Drugs 31: 369–461
Regårdh CG, Borg KO, Johansson R, Johansson G, Palmer L (1974) Pharmacokinetic studies on the selective beta-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm 2: 347–364
Högstedt S, Lindberg B, Peng DR, Regårdh CG, Rane A (1985) Pregnancy induced increase in metoprolol metabolism. Clin Pharmacol Ther 37: 688–692
Lindeberg S, Sandström B, Lundborg P, Regårdh CG (1984) Disposition of the adrenergic blocker metoprolol in the late pregnant woman, the amniotic fluid, the cord blood and neonate. Acta Obstet Gynecol Scand Suppl 118: 61–64
Lundborg P, Ågren G, Ervik M, Lindeberg S, Sandström B (1981) Disposition of metoprolol in the newborn. Br J Clin Pharm 12: 589–600
Regårdh CG, Ek L, Hoffman KJ (1979) Plasma levels and beta-blocking effect of alfa-hydroxy-metoprolol-metabolite of metoprolol in the dog. J Pharmacokinet Biopharm 7: 471–479
Ervik M, Hoffman KJ, Kyhlberg-Hanssen K (1981) Selected ion monitoring of metoprolol and two metabolites in plasma and using deuterated internal standards. Biomed Mass Spectrom 8: 322–326
Regårdh CG, Landahl S, Larsson M, Lundborg P, Steen B, Hoffman KJ, Lagerström PO (1983) Pharmacokinetics of metoprolol and its metabolite alfa-OH-metoprolol in healthy, non-smoking, elderly individuals. Eur J Clin Pharmacol 24: 221–226
van Otterlo LC, Wladimiroff IW, Wallenburg HCS (1977) Relationship between fetal urine production and amniotic fluid in normal pregnancy and pregnancy complicated by diabetes. Br J Obstet Gynaecol 84: 205–209
Seeds AE (1980) Current concepts of amniotic fluid dynamics. Am J Obstet Gynecol 138: 575–586
Szeto HH, Mann LI, Bhakthavathsalan A, Liu M, Inturrisi CE (1978) Meperidine pharmacokinetics in the maternalfetal unit. J Pharmacol Exp Ther 106: 448–459
Depp R, Kind AC, Kirby WM, Johnson WL (1970) Placental passage of methicillin and dicloxacillin into the fetus and amniotic fluid. Am J Obstet Gynecol 107: 1054–1057
Basso A, Fernandez A, Althabe O, Sabini G, Piriz H, Belitzky R (1977) Passage of mannitol from mother to amniotic fluid and fetus. Obstet Gynecol 49: 628–631
van Petten GR, Mears GJ, Mathison HJ (1978) Transfer of beta-blocking drugs from the amniotic fluid to the fetal and maternal circulation. J Pharmacol Exp Ther 207: 641–649
Thorley KJ, McAinsh J, Cruickshank JM (1981) Atenolol in the treatment of pregnancy-induced hypertension. Br J Clin Pharm 12: 725–730
O'Hare MF, Murnaghan GA, Russel CJ, Leahey WJ, Varma MPS, McDevitt DG (1980) Sotalol as a hypotensive agent in pregnancy. Br J Obstet Gynaecol 87: 814–820
Cottrill CM, McAllister RG, Gettes L, Noonan JA (1977) Propranolol therapy during pregnancy, labor and delivery: Evidence for trans-placental drug transfer and impaired neonatal drug dispisition. Pediatrics 91: 812–814
Kuhnert BR, Kuhnert PM, Philipson EH, Syrakuse CD (1985) Disposition of meperidine and normeperidine following multiple doses during labor. Am J Obstet Gynecol 151: 410–415
Brown WK, Bell GC, Alper MH (1976) Acidosis, local anesthetics and the newborn. Obstet Gynecol 48: 27–30
Biehl D, Shnider S, Levinson G, Callender K (1978) Placental transfer on lidocaine. Anesthesiology 48: 409–412
Woods DL, Malan AF (1983) Side-effects of labetalol in newborn infants. Br J Obstet Gynaecol 90: 876
Lindeberg S, Axelsson O, Lindberg BS, Lindmark G, Ludviksson K, Sandström B (1985) Effect of metoprolol in combination with hydralazine on fetal heart rate patterns during hypertensive pregnancy and delivery. Clin Exper Hyper B 4: 87–94
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lindeberg, S., Lundborg, P., Regårdh, C.G. et al. Disposition of the adrenergic blocker metoprolol and its metabolite OH-metoprolol in maternal plasma, amniotic fluid and capillary blood of the neonate. Eur J Clin Pharmacol 33, 363–368 (1987). https://doi.org/10.1007/BF00637631
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637631